The most recent guidelines suggest using integrase strand-transfer inhibitors (InSTIs) as the preferred antiretroviral regimens for naive HIV-infected individuals. However, resistance to InSTIs is not monitored in many centres at baseline. This study aimed to evaluate the prevalence of InSTI resistance substitutions in newly diagnosed patients with acute/recent HIV infection.
Introduction
Acute/recent HIV infection represents 20% -25% of newly diagnosed HIV patients in Spain and other European countries. However, these cases contribute disproportionately to HIV transmission due to the high viral load (VL) in this phase and the fact that many patients are unaware of the infection. 1 Primary HIV infection can be symptomatic in up to 80% -90% of cases and rapid VL reductions improve symptoms, preserve the immune system, reduce the viral reservoir and prevent/reduce HIV transmission. 2 Due to these facts, ART is frequently initiated early after diagnosis and resistance tests are frequently not available at the time of ART initiation.
Overall transmitted drug resistance (TDR) to NRTIs, NNRTIs and PIs has been reported to be 10% of cases of acute/recent newly diagnosed patients in our clinical context. 3 TDR to integrase strand-transfer inhibitors (InSTIs) is believed to be very low and has been very rarely reported to date. 4 -6 Small-cohort studies performed in the USA and other countries failed to identify naive subjects with primary signature InSTI substitutions, but some did find small proportions of secondary substitutions or polymorphisms, sometimes related to specific HIV subtypes. 7, 8 In a recent article, Casadellà et al. 9 found no signature substitutions circulating in Europe before the introduction of InSTIs. However, they also found that polymorphic and accessory substitutions contributing to InSTI resistance were not rare. 9 These substitutions may be associated with a reduced activity of some InSTIs and may impact on ART regimen choice in Europe, particularly in the context of high VL, as is the case of patients with acute/recent infection.
InSTIs are progressively becoming the preferred regimen for HIV-infected patients in many guidelines, 10,11 so they will be Due to the widespread use of this family of drugs, a baseline resistance test to InSTIs has been added to the baseline resistance test in our institution since 12 May 2015. The aim of our study was to evaluate the prevalence of InSTI resistance substitutions in newly diagnosed patients with acute/recent HIV infection in order to guide the initial ART combination in this specific population.
Patients and methods

Patients and resistance testing
The acute/recent HIV infection cohort of the Hospital Clinic (tertiary university hospital in Barcelona, Spain, with 5000 HIV-positive patients on active follow-up) is an ongoing prospective cohort of documented acute/recent HIV infection (,6 months) with almost 500 patients enrolled since 1997. Briefly, the inclusion criteria were detectable viraemia with a negative HIV serology result, incomplete western blot test or documented seroconversion within the 6 months prior to the first evaluation. The cohort has been described elsewhere.
3 In this study, we included patients enrolled between 12 May 2015 (initiation of InSTI genotyping test at baseline) and 12 May 2016.
Samples were pyrosequenced in a 454 GS Junior System (Roche Diagnostics) using Titanium chemistry. Genotypic information was analysed by DeepChek w HIV v1.4 (ABL and TherapyEdge) using a 1% frequency threshold for variant detection. All substitutions/polymorphisms with .10 points according to the HIV drug resistance database from Stanford University were listed. Substitutions/polymorphisms present in any proportion were reported; substitutions/polymorphisms present in .20% of sequences were considered clinically relevant. Patients with detected InSTI substitutions/polymorphisms were compared with patients not carrying them.
Categorical variables are expressed as frequency (%). Continuous variables are expressed as median (IQR). To compare categorical variables between the two groups, the Fisher exact test was used. To compare continuous variables between the two groups, the Mann -Whitney test was performed. Data were analysed with R software, version 3.2.3.
Ethics
The acute/recent HIV infection cohort of Hospital Clinic was approved by the Ethics Committee of Hospital Clinic. All patients provided written informed consent before inclusion in the cohort.
Results
Over a 1 year period (12 May 2015 to 12 May 2016), 5 out of 36 consecutive patients (13.89%, 95% CI ¼ 4.67 -29.5) in our cohort of acute/recent HIV infection were detected as having strains carrying InSTI polymorphic or accessory resistance substitutions (Table 1) . Four patients were from Western Europe (two from Italy and two from Spain) and one was from Venezuela. There was no known epidemiological link between them. All patients were MSM, with a median age of 37 years, infected with subtype B strains, with VL ranging from 2.92 to 6.95 log 10 copies/mL and a median of 436 CD4 T cells/mm 3 at diagnosis. All were HLA-B5701 negative. Three out of four cases had X4 tropism.
Four patients had the 157Q polymorphism [conferring lowlevel resistance to raltegravir and elvitegravir according to the Stanford HIV drug resistance database (score of 15 points)] and one patient had the Q95K substitution [conferring potential lowlevel resistance to raltegravir and elvitegravir (score of 10 points)]. In all cases, the InSTI polymorphism/substitution was present in a high proportion of RNA copies (mutational load .95% of VL in all cases). One of the patients also had the 138A substitution detected for NNRTI; no other resistance substitution was detected.
There were no major viral or epidemiological differences compared with patients without InSTI polymorphisms/substitutions. Of note, resistance to other antiretroviral (ARV) families was detected in one of the cases carrying InSTI polymorphisms (20%, 138A substitution for NNRTI) and in 12.9% of other patients not carrying InSTI polymorphisms/substitutions. If all four families of ARV are considered, 9 out of 36 patients (25%) had at least one polymorphism or resistance substitution with .10 points for the respective ARV family, according to the Stanford HIV drug resistance database. Comparisons of acute/recent cases included in this study, with and without InSTI polymorphisms/substitutions, are shown in Table 2 .
Discussion
In this 12 month period, 5 out of 36 (13.89%) consecutive patients with acute/recent HIV infection were found to carry InSTI polymorphisms or resistance substitutions. All these cases were detected in subtype B infections, the most frequent subtype circulating in Europe among MSM.
Casadellà et al. 9 reported the primary resistance to HIV InSTIs in Europe, on behalf of a large European programme (the SPREAD programme), in samples collected between 2006 and 2007, before the introduction of InSTIs into clinical practice. In that study, it was found that 14.3% of sequences had InSTI polymorphic or accessory resistance substitutions, detected by highthroughput sequencing. As in our cohort, the majority of cases were subtype B (67%), male (83%) and MSM (64.8%) patients.
Signature InSTI substitutions, such as Y143R/C, N155H or Q148K/R/H, were not detected in our cohort. This is in line with the reports of overall low or null signature TDR rate for this family so far.
4 -6 E157Q is a polymorphic substitution that is weakly selected in patients receiving raltegravir and is selected in vitro by elvitegravir. E157Q reduces raltegravir susceptibility by 5-fold and elvitegravir susceptibility by 2-fold. E157Q has been reported to be rapidly selected during short-term low-level replication of raltegravir-based regimens. 12 More recently, it has also been described that E157Q may act as a compensatory substitution for R263K-induced resistance to dolutegravir. 13 Q95K is a non-polymorphic accessory InSTI resistance substitution selected in patients receiving raltegravir and in vitro by elvitegravir. Alone, it has little effect, if any, on InSTI susceptibility, but in the context of the extremely high VL observed during primary HIV infection (PHI), the effect is unknown. This substitution has also been described to enhance N155H-mediated InSTI resistance and to improve viral replication capacity.
14 Dolutegravir susceptibility seems not to be affected by Q95K or E157Q. Since InSTI resistance was rarely tested until recently in most centres, the real clinical impact of these polymorphisms or accessory substitutions for naive patients initiating ART, or during simplification strategies, is unknown.
In our cohort, TDR to other ARV families represented 9% of cases between 1997 and 2012, 3 so prevalence of polymorphisms or accessory substitutions conferring low-level resistance to InSTIs would be even higher than the resistance detected for the other families, and the large majority of patients are starting InSTI-based ART regimens. Of note, three out of four cases were infected with X4 strains and if all the four main families of ARV are considered, one out of four patients would have a resistant substitution or polymorphism with ≥10 points according to the Stanford HIV drug resistance database. This highlights the relevance of baseline tropism and resistance testing for all ARV families in this clinical context. The preferred regimen to be started and the impact on ART efficacy for the different InSTIs in particular clinical settings (such as acute/recent infection with high VL) are unknown. The ART regimen should be carefully selected in these cases and raltegravir and elvitegravir prescribed with caution, alongside close monitoring of the virological response. If ART is initiated without resistance test results, dolutegravir seems the most appropriate drug due to its higher genetic barrier. The impact of these polymorphic and accessory substitutions on newer InSTIs such as cabotegravir and bictegravir is unknown, although presumably their activity should not be affected. Prospective follow-up of these cases will provide clinical data on efficacy where these InSTI polymorphic and accessory substitutions are present.
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